SEARCH:   Advanced

Blood, 1 July 2007, Vol. 110, No. 1, pp. 450-460. Prepublished online as a Blood First Edition Paper on March 19, 2007; DOI 10.1182/blood-2006-11-057935. This Article Full Text (PDF) All Versions of this Article: blood-2006-11-057935v1 110/1/450    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kochenderfer, J. N. Articles by Gress, R. E. Search for Related Content PubMed PubMed Citation Articles by Kochenderfer, J. N. Articles by Gress, R. E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 28, 2006 Accepted March 16, 2007 Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific anti-tumor immunity from T cell populations undergoing homeostatic peripheral expansion after BMT James N. Kochenderfer*, Jessica L. Simpson, Christopher D. Chien, and Ronald E. Gress Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States * Corresponding author; email: kochendj{at}mail.nih.gov. Development of CD8+ T cell responses targeting tumor-associated antigens after autologous stem cell transplants (ASCT) might eradicate residual tumor cells and decrease relapse rates. Because thymic function dramatically decreases with aging, T cell reconstitution in the first year after ASCT in middle-aged patients occurs primarily by homeostatic peripheral expansion (HPE) of mature T cells. To study antigen-specific T cell responses during HPE, we performed syngeneic bone marrow transplants (BMT) on thymectomized mice then vaccinated the mice with peptides plus CpG-containing oligodeoxynucleotides (CpG) in incomplete Freund's adjuvant and treated the mice with systemic interleukin-2 (IL-2). When CD8+ T cell responses were measured ex vivo, up to 9.1% of CD8+ T cells were specific for tumor-associated epitopes. These large T cell responses were generated by synergism between CpG and IL-2. When we injected mice subcutaneously with tumor cells 14 days after BMT and then treated them with peptide+CpG-containing vaccines plus systemic IL-2, survival was increased and tumor growth was inhibited in an epitope-specific manner. Depletion of CD8+ T cells eliminated epitope-specific anti-tumor immunity. This is the first report to demonstrate that CD8+ T cell responses capable of executing anti-tumor immunity can be elicited by CpG-containing vaccines during HPE. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-P. Fermand Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379. [Abstract] [Full Text] [PDF] J. N. Kochenderfer and R. E. Gress A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies Experimental Biology and Medicine, October 1, 2007; 232(9): 1130 - 1141. [Abstract] [Full Text] [PDF] C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020